Literature DB >> 3519828

Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide.

M Jacewicz, H Clausen, E Nudelman, A Donohue-Rolfe, G T Keusch.   

Abstract

A glycolipid that specifically binds shigella toxin was isolated from both HeLa cells and rabbit jejunal mucosa and identified as globotriaosylceramide (Gb3) by its identical mobility on HPTLC to authentic erythrocyte Gb3. Toxin also bound to a band tentatively identified as alpha-hydroxylated Gb3. In addition, toxin bound to P1 antigen present in group B human erythrocyte glycolipid extracts. The common feature of the three binding glycolipids is a terminal Gal alpha 1----4Gal disaccharide linked beta 1----4 to either Glc or GlcNAc. Globoisotriaosylceramide, which differs from Gb3 only in possessing a Gal alpha 1----3Gal terminal disaccharide, and LacCer, which lacks the terminal Gal residue of Gb3, were incapable of binding the toxin. Binding was shown to be mediated by the B subunit by the use of isolated toxin A and B subunits and monoclonal subunit-specific antibodies. Gb3-containing liposomes competitively inhibited the binding of toxin to HeLa cell monolayers but did not inhibit toxin-induced cytotoxicity. These studies show an identical carbohydrate-specific glycolipid receptor for shigella toxin in gut and in HeLa cells. The toxin B subunit that mediates this binding has also been shown to recognize a glycoprotein receptor with different sugar specificity. Thus, we have demonstrated that the same small (Mr 6,500) B subunit polypeptide has two distinctive carbohydrate-specific binding sites. The Gal alpha 1----4Gal disaccharide of the glycolipid toxin receptor is also recognized by the Gal-Gal pilus of uropathogenic E. coli. This suggests the possibility that the pilus and toxin B subunit contain homologous sequences. If this is true, it may be possible to use the purified Gal-Gal pilus to produce toxin-neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3519828      PMCID: PMC2188132          DOI: 10.1084/jem.163.6.1391

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  28 in total

Review 1.  Shigella toxin(s): description and role in diarrhea and dysentery.

Authors:  G T Keusch; A Donohue-Rolfe; M Jacewicz
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

2.  Structures of ceramide tetrasaccharides from various sources: uniqueness of rat kidney ceramide tetrasaccharide.

Authors:  B Siddiqui; J Kawanami; Y T Li; S Hakomori
Journal:  J Lipid Res       Date:  1972-09       Impact factor: 5.922

3.  A new glycolipid antigen isolated from human erythrocyte membranes reacting with antibodies directed to globo-N-tetraosylceramide (globoside).

Authors:  R Kannagi; M N Fukuda; S Hakomori
Journal:  J Biol Chem       Date:  1982-04-25       Impact factor: 5.157

4.  Quantitative isolation of total glycosphingolipids from animal cells.

Authors:  T Saito; S I Hakomori
Journal:  J Lipid Res       Date:  1971-03       Impact factor: 5.922

5.  Shigella toxin and the pathogenesis of shigellosis.

Authors:  G T Keusch; A Donohue-Rolfe; M Jacewicz
Journal:  Ciba Found Symp       Date:  1985

6.  Animal toxicity of Shigella dysenteriae cytotoxin: evidence that the neurotoxic, enterotoxic, and cytotoxic activities are due to one toxin.

Authors:  K Eiklid; S Olsnes
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

7.  Molecular basis of Escherichia coli colonization of the upper urinary tract in BALB/c mice. Gal-Gal pili immunization prevents Escherichia coli pyelonephritis in the BALB/c mouse model of human pyelonephritis.

Authors:  P O'Hanley; D Lark; S Falkow; G Schoolnik
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

8.  A glycolipid antigen associated with Burkitt lymphoma defined by a monoclonal antibody.

Authors:  E Nudelman; R Kannagi; S Hakomori; M Parsons; M Lipinski; J Wiels; M Fellous; T Tursz
Journal:  Science       Date:  1983-04-29       Impact factor: 47.728

9.  Gal-Gal pyelonephritis Escherichia coli pili linear immunogenic and antigenic epitopes.

Authors:  M A Schmidt; P O'Hanley; G K Schoolnik
Journal:  J Exp Med       Date:  1985-04-01       Impact factor: 14.307

10.  Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies.

Authors:  A Donohue-Rolfe; G T Keusch; C Edson; D Thorley-Lawson; M Jacewicz
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

View more
  134 in total

1.  Development of recombinant B subunit of Shiga-like toxin 1 as a probe to detect carbohydrate ligands in immunochemical and flowcytometric application.

Authors:  S Miyashita; Y Matsuura; D Miyamoto; Y Suzuki; Y Imai
Journal:  Glycoconj J       Date:  1999-11       Impact factor: 2.916

2.  Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide.

Authors:  T Waddell; A Cohen; C A Lingwood
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

3.  A system for production and rapid purification of large amounts of the Shiga toxin/Shiga-like toxin I B subunit.

Authors:  S B Calderwood; D W Acheson; M B Goldberg; S A Boyko; A Donohue-Rolfe
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

4.  Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron.

Authors:  K Ramotar; B Boyd; G Tyrrell; J Gariepy; C Lingwood; J Brunton
Journal:  Biochem J       Date:  1990-12-15       Impact factor: 3.857

5.  Shiga toxin 2 and flagellin from shiga-toxigenic Escherichia coli superinduce interleukin-8 through synergistic effects on host stress-activated protein kinase activation.

Authors:  Dakshina M Jandhyala; Trisha J Rogers; Anne Kane; Adrienne W Paton; James C Paton; Cheleste M Thorpe
Journal:  Infect Immun       Date:  2010-05-03       Impact factor: 3.441

6.  Pathogenesis of Shigella diarrhea. XVI. Selective targetting of Shiga toxin to villus cells of rabbit jejunum explains the effect of the toxin on intestinal electrolyte transport.

Authors:  G Kandel; A Donohue-Rolfe; M Donowitz; G T Keusch
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

7.  Identification of amino acids critical for the cytotoxicity of Shiga toxin 1 and 2 in Saccharomyces cerevisiae.

Authors:  Rong Di; Eric Kyu; Varsha Shete; Hemalatha Saidasan; Peter C Kahn; Nilgun E Tumer
Journal:  Toxicon       Date:  2010-12-22       Impact factor: 3.033

Review 8.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid.

Authors:  L L Cooling; K E Walker; T Gille; T A Koerner
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

10.  Expression and purification of Shiga-like toxin II B subunits.

Authors:  D W Acheson; S A De Breucker; M Jacewicz; L L Lincicome; A Donohue-Rolfe; A V Kane; G T Keusch
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.